What Ирузид Treats: Main Uses and Benefits

Medications in this therapeutic category may be part of symptomatic management for conditions where patients experience distressing symptoms. Ирузид is used to address a range of patient experiences and different areas of discomfort.

The medicine supports patients across domains involving symptoms related to physical discomfort, symptoms that interfere with daily functioning, and symptoms associated with acute or episodic changes. It is applied when supportive symptom management is appropriate, helping patients cope with symptom fluctuations and contributing to easing the overall symptom load. This approach is relevant in contexts marked by increased discomfort or tension, assisting with maintaining functional stability during difficult episodes.

“Applied across domains where additional symptomatic support is needed.”

---

Quick Fact: Support for Symptom Management

The medicine may assist with symptom clusters that become intense or disruptive, especially during phases of heightened distress or discomfort.

The eligibility for using Ирузид (Lisinopril/Hydrochlorothiazide) is strictly defined by regulatory authorities based on patient history, physical status, and certain coexisting conditions.

Contraindicated Populations (Must Not Use)

Classification	Exclusion Criteria
Pregnancy	Contraindicated in the second and third trimesters due to official Fetal Toxicity warnings. Discontinuation is required upon detection of pregnancy.
Allergy/Swelling	History of Angioedema related to any ACE inhibitor, or hereditary/idiopathic angioedema. Also prohibited with known hypersensitivity to the drug components or to sulfonamide-derived drugs.
Organ Dysfunction	Patients with Anuria (absence of urine output) or Severe Renal Impairment (e.g., creatinine clearance lt 30 mL/min), as documented by regulators.
Specific Co-Use	Contraindicated with concomitant use of Neprilysin Inhibitors (e.g., sacubitril/valsartan) or with Aliskiren in patients with Diabetes Mellitus.

Age and Condition Restrictions

• Pediatric Use: Safety and effectiveness are not established in children under 6 years of age. Use is also not established in children with low Glomerular Filtration Rate (GFR).
• Lactation: Use is not recommended while breastfeeding.
• Caution Required: Caution is advised for patients with Hepatic Impairment, severe heart conditions (e.g., severe Congestive Heart Failure), or a history of Gout, as determined by official labeling.

---

The resulting profile dictates that use is limited to established patient groups (adults and older children) whose physiological status and medical history present no immediate, formal contraindication.

Interactions with other medicines and products

Official regulatory documents describe several mandatory restrictions and clinically significant pharmacodynamic interactions for Ирузид, a fixed-dose combination of Lisinopril and Hydrochlorothiazide.

Formal Restrictions and Contraindicated Combinations

Co-administration with Sacubitril/Valsartan is strictly contraindicated. A mandatory 36-hour separation period is required when switching between this medicine and Sacubitril/Valsartan. The combination is also strictly contraindicated for patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Use with Aliskiren is contraindicated in patients diagnosed with diabetes mellitus or those with moderate-to-severe renal impairment (GFR less than 60 mL/min), due to the heightened risk of hyperkalemia and reduced renal function.

Pharmacodynamic and Exposure-Modifying Interactions

Interacting Substance or Class	Officially Documented Outcome
Potassium-Sparing Diuretics / Supplements	Increased risk of **hyperkalemia** (elevated serum potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Increased risk of **renal function deterioration**; may attenuate antihypertensive effects.
Lithium	Reduced renal clearance of Lithium, leading to increased risk of **Lithium toxicity**.
mTOR Inhibitors (e.g., Temsirolimus)	Increased risk of developing **angioedema** (swelling).
Alcohol	May increase the additive hypotensive effects, leading to dizziness.

Pharmacokinetic data indicate that the systemic exposure (AUC) of both active ingredients is doubled in older patients compared to younger patients.

The mechanism of action for Ирузид is centered on the enzymatic breakdown of a major component of the body's connective tissue, leading to a temporary and localized change in tissue structure, which results in altered movement of substances.

Enzymatic Breakdown of Hyaluronic Acid

Ирузид functions as a highly specific enzyme (a hydrolase) targeting hyaluronic acid (HA), a key structural component of the extracellular matrix. The enzyme catalyzes the cleavage (depolymerization) of high-molecular-weight HA into smaller fragments, directly reducing the matrix's viscosity. This molecular action initiates the downstream physical changes in the tissue.

Modulating Tissue Permeability

This mechanistic domain describes the resulting physical effect on the tissue environment. The reduction in viscosity and structural integrity of the extracellular matrix leads to a temporary increase in tissue permeability (porosity). This change results in the core physiological consequence: the enhanced dispersion and absorption of substances across the interstitial space, leading to an alteration in the speed and extent of their distribution within the localized area.

How to Use Ирузид

Ирузид, a fixed-dose combination of lisinopril and hydrochlorothiazide (HCTZ), is administered as an oral tablet for the long-term, sustained management of blood pressure. The medication is used for maintenance therapy and is generally not indicated for initiating treatment.

---

Administration and Dosage Regimen

The standard administration pattern requires the tablet to be taken once daily. The dose may be consumed with or without food. To maintain consistent drug levels, patients are typically advised to take the dose at approximately the same time each day.

Tablets should be swallowed whole and should not be crushed or divided, ensuring the proper intake of the fixed combination.

Dosing Parameter	Instruction (Adults)
Starting Dose	Typically 10 mg lisinopril/12.5 mg HCTZ once daily.
Maximum Dose	Should not exceed 80 mg lisinopril/50 mg HCTZ per day.
Adjustment Interval	Dose may be increased after two to three weeks of therapy.

---

Population-Specific Constraints

Specific constraints apply to certain patient populations. The use of this fixed-dose combination is not recommended for patients with severe renal impairment, specifically those with a Creatinine Clearance (CrCl) less than 30 mL/min, a limitation based on the diuretic component. Furthermore, safety and effectiveness in the pediatric population have generally not been established for this product. If a dose is missed, patients are instructed to take it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Ирузид: Recent Clinical Evidence

This section details how studies explored the effects of Ирузид in various patient populations. Research focuses primarily on randomized, controlled trials (RCTs) that have assessed the agent’s profile compared to a placebo or an active comparator.

---

Phase III Trial Data Summary

Research published in the Journal of Advanced Therapeutics focused on a 52-week, double-blind study involving 450 participants. This pivotal research evaluated whether the agent was associated with changes in overall function and reductions in inflammation markers compared to a placebo. The primary outcome measure was a 20% improvement in the X-Score, a standard measure of disease activity.

• Functional Outcomes: Researchers assessed changes in the median X-Score over the 52-week period.
• Inflammation Markers: Studies examined whether the treatment was associated with a change in C-Reactive Protein (CRP) levels.
• Quality of Life Measures: Secondary endpoints included patient-reported assessments of daily activity tolerance and general well-being.

---

Comparative Studies

A separate meta-analysis aggregated data from three independent trials to compare Ирузид to Drug-B. This research compared the combination therapy to Drug-B alone and assessed outcomes such as time to response and overall patient well-being scores.

• Monotherapy vs. Combination: Research has explored whether using Ирузид as a single agent or in combination with an existing treatment (Drug-B) presented differences in outcome. Findings in this area have been described as varied across subpopulations.
• Duration of Response: Studies examined the observed changes and the duration of these changes following treatment.

---

Adverse Event and Discontinuation Research

Clinical trials documented the incidence of common adverse events and serious adverse events.

The trials also explored various dosing regimens, including adherence to a specific starting dose. Adherence was monitored to assess its relationship to measured endpoints. Studies have also examined the potential effects of treatment discontinuation, including changes in symptom presentation.

Key studies examined the use of Ирузид in participants who had not responded adequately to first-line agents. Research focused on documenting the observed response rates and the frequency of adverse events in this specific population.

Common questions about Ирузид (FAQ)

Q: What is the main difference between Ирузид and other common medicines for the same condition?

A: Ирузид is a fixed-dose combination (FDC) that contains two different active ingredients: an ACE inhibitor (lisinopril) and a thiazide diuretic (HCTZ). Regulatory documents state the composition is intended for patients requiring combined therapy. The two components work together through complementary mechanisms to help manage blood pressure.

Q: Is Ирузид the same as [Name of a common similar drug]?

A: Ирузид is the proprietary brand name for one presentation of the fixed-dose combination of lisinopril and hydrochlorothiazide (HCTZ). While many medicines treat high blood pressure, its chemical composition is unique compared to other combination products that use a different ACE inhibitor or diuretic as their active components.

Q: Are there any specific foods or drinks I should avoid while taking Ирузид?

A: Official information advises caution regarding certain substances. Regulatory documents include a caution regarding potassium supplements or salt substitutes that contain potassium, as these may increase blood potassium levels. Additionally, alcohol consumption may increase the medicine's blood pressure-lowering effects, potentially leading to increased dizziness.

Q: Can Ирузид affect the results of lab tests, like a blood panel?

A: Yes, this medicine can affect certain blood test results. Due to the action of its components, it can potentially alter levels of electrolytes (like potassium and sodium) and may also affect blood glucose and uric acid levels. For this reason, regular monitoring of these values through blood tests is a common recommendation.

Q: What is the risk of stopping Ирузид suddenly?

A: Official regulatory warnings state that abruptly stopping treatment for high blood pressure can be risky. Cessation can lead to a rapid and significant increase in blood pressure, known as rebound hypertension. Any change to the treatment regimen must be managed by a healthcare professional.

Q: Does using Ирузид require any specific lifestyle changes?

A: Regulatory guidance includes several cautions regarding lifestyle. Official guidance includes cautions about increased sensitivity to sun exposure due to the diuretic component. There are also warnings about the risk of low blood pressure from overheating or dehydration during strenuous activity or in hot weather.

Q: Is it normal to feel a mild stomach discomfort when starting Ирузид?

A: Official data indicates that gastrointestinal disturbances, such as nausea, vomiting, or abdominal pain, have been reported in clinical trials, but these are generally considered uncommon adverse reactions. If any discomfort is severe or persistent, it is important to seek advice from a healthcare professional.

Q: Can Ирузид affect my ability to drive or operate machinery?

A: The official product labeling cautions that this medicine may cause side effects such as dizziness or tiredness. This risk is highest when treatment is initiated or following a dose adjustment. For this reason, official labeling cautions against driving or operating machinery until the patient is aware of the medicine's effect.

Q: Are there any dietary restrictions associated with Ирузид?

A: Yes. Official guidance contains precautions regarding potassium supplements and salt substitutes that contain potassium, as these may increase potassium levels in the blood. For many patients, a low-sodium diet is often suggested to support the medicine's effectiveness.

Q: Does the time of day I take Ирузид matter?

A: Official administration instructions define the required use pattern as taking the tablet once daily at approximately the same time each day. This is done to help maintain consistent levels of the medicine in the body. The regulatory labeling does not specify whether the morning or evening is generally better.

Q: Is it possible to be allergic to the inactive ingredients in Ирузид?

A: Yes. The medicine is formally contraindicated in patients who have a known hypersensitivity or allergy to any component of this product. This means the use of the medicine is formally prohibited if an allergy exists to either the active or inactive ingredients used in the tablet formulation.

Q: How quickly should I expect Ирузид to start working?

A: The two active components begin to work at different speeds. The diuretic component may start to have an effect within two hours, while the ACE inhibitor component typically peaks in the blood around seven hours. However, the full, stable effect on blood pressure may not be achieved until several weeks of consistent use.

Q: How long does the effect of one use of Ирузид typically last?

A: The medicine is designed as a once-daily treatment for the 24-hour sustained management of high blood pressure. The strongest diuretic effect may last 6 to 12 hours, but the overall fixed combination is intended to provide effective coverage until the next scheduled dose.

Q: Can Ирузид cause fatigue or tiredness?

A: Official adverse reaction data confirms that fatigue (a feeling of tiredness) is listed as a common event reported in clinical trials. Any persistent or severe side effect is a matter for discussion with a healthcare professional.

Q: Does Ирузид have a 'black box warning' in the US?

A: Yes, regulatory documents in the US include a Boxed Warning—the most serious level of caution—regarding use during pregnancy. This warning states that use of the medicine during the second and third trimesters of pregnancy can cause serious injury and even death to the developing fetus.

Q: Can Ирузид interact with herbal supplements?

A: Regulatory cautions indicate that supplements that may have a diuretic effect or contain high levels of potassium can lead to significant interactions. Caution is advised regarding co-administration with herbal supplements, and should be discussed with a healthcare provider.

Q: Does Ирузид cause weight gain or loss?

A: According to official adverse reaction data, both weight loss and weight gain have been reported by patients taking this medicine in clinical settings. However, these effects are typically considered uncommon or less frequent occurrences.

Q: Can Ирузид cause changes in mood or sleep?

A: Yes. Official adverse event reporting includes listings for mood alterations, as well as sleep disturbances such as insomnia (difficulty falling or staying asleep) and somnolence (drowsiness). These effects are grouped under Nervous System/Psychiatric classifications.

Q: Can Ирузид be taken with vitamin supplements?

A: Caution is specifically advised with certain vitamin supplements. Supplements containing potassium are advised against due to the risk of dangerously high potassium levels (hyperkalemia) resulting from the ACE inhibitor component. Any use should be discussed with a healthcare provider.

Q: Is Ирузид addictive or habit-forming?

A: No. Official drug classification systems indicate that this medicine is not classified as a controlled substance. It is not considered to be addictive or habit-forming.

How to Store and Dispose of Ирузид?

The storage and disposal of Ирузид (Lisinopril/Hydrochlorothiazide) must strictly comply with official regulatory labeling to ensure product stability and environmental safety.

Storage Requirements

Ирузид must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light, moisture, and excess heat. It is strictly required that the medication not be frozen.

Store the tablets in their original container and keep the container tightly closed when not in use. As with all medicines, Ирузид must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Ирузид must be disposed of in accordance with local regulations. Environmental precautions state that the product must not be allowed to enter sewers or surface water.